Conference will be held Feb. 11-13 at the Waldorf-Astoria Hotel in New York
NEW YORK, Jan. 24 /PRNewswire/ -- Gerson Lehrman Group (GLG) and the Biotechnology Industry Organization (BIO) today announced a collaborative agreement designed to strengthen the access to clinical information and insights at the tenth annual BIO CEO & Investor Conference.
"We're thrilled to have this unique partnership opportunity with BIO in their tireless efforts to increase the relevant and timely dissemination of some of the most highly technical and challenging scientific issues of today," said Alexander Saint-Amand, Chief Executive Officer of GLG. "Our company's long-standing mission is to empower decision-makers by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."
Through this partnership, BIO will tap into GLG's network of experts from around the world in order to identify the most relevant thought leaders to discuss the latest issues and trends affecting drug development and clinical design in the biotechnology industry.
"Gerson Lehrman Group is an ideal partner for BIO's annual investment conferences with deep access to the clinical experts and investigators who can bring insights to pipeline research and current clinical practices," said James C. Greenwood, president and CEO of BIO. "Our Therapeutic Workshops and Business Roundtable discussions focus on educating investors and industry management on the issues that face product innovation, capitalization and commercialization."
The BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference features issue-oriented plenary sessions, educational sessions on therapeutic areas and business issues, company presentations, one-on-one meetings, and networking opportunities.
To see the latest updates on 2008 programming and speakers for BIO CEO & Investor Conference, please visit http://ceo.bio.org/opencms/ceo/2008/index.jsp.
About Gerson Lehrman Group
Gerson Lehrman Group (GLG) provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. GLG's unparalleled network of the world's leading expert consultants, known as the GLG Councils, includes more than 175,000 subject-matter experts who educate and provide insight to decision-makers through a wide range of consulting methods, including telephone consultations, expert surveys and seminars. GLG has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about GLG, please visit http://www.glgroup.com.
About BIO and the Tenth Annual BIO CEO & Investor Conference
Now in its tenth year, the BIO CEO & Investor Conference is the largest
independent biotechnology investor conference focused on publicly-traded
companies. The conference provides a neutral forum where institutional
investors, industry analysts, and senior biotechnology executives have the
opportunity to shape the future investment landscape of the biotechnology
industry. The conference features issue-oriented plenary sessions,
educational sessions focused on hot therapeutic areas and key business
issues, company presentations, one-on-one meetings, and networking
opportunities. The conference is hosted by the Biotechnology Industry
Organization (BIO), representing more than 1,150 biotechnology companies,
academic institutions, state biotechnology centers and related
organizations across the United States and 31 other nations. BIO produces
the BIO International Convention, the world's largest gathering of the
Gerson Lehrman Group
Margaret M. Molloy
|SOURCE Gerson Lehrman Group|
Copyright©2008 PR Newswire.
All rights reserved